Rheumatology Advance Access first published online on August 28, 2006
This version published online on April 21, 2008
Rheumatology, doi:10.1093/rheumatology/kel216a
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists
Harold Wood Hospital, BHR Trust, Romford, 1Gubbins Lane Surgery, Harold Wood, 2Ninewells Hospital, Dundee, 3Musgrave Park Hospital, Belfast, 4Manchester Royal Infirmary, Manchester, 5Royal College of Nursing Rheumatology Forum, London, 6Litchdon Health Centre, Barnstaple, 7Norfolk & Norwich University Hospital and University of East Anglia, 8Norfolk & Norwich University Hospital, Norwich, 9National Rheumatoid Arthritis Society, Maidenhead and 10Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK.
Correspondence to:
K. Chakravarty, Harold Wood Hospital, BHR NHS Trust, Romford, Essex RM7 OBE, UK. E-mail: Kuntal.Chakravarty@bhrhospitals.nhs.uk
KEY WORDS: DMARD, Guideline, Multidisciplinary, Multi professional
| The first 10% of the full text of this article appears below. |
 |
Scope and purpose of the guideline |
|---|
Inflammatory arthritis and especially rheumatoid arthritis (RA) is common and affects 1% of the population. The prognosis of RA remains uncertain as it runs a variable and unpredictable course. Several longitudinal studies have demonstrated the progressive course of RA and new research has emphasized the need for early intervention with disease-modifying anti-rheumatic drugs (DMARDs) to prevent long-term disability.
The development of Clinical Guidelines is the first step towards earlier diagnosis and treatment. This multidisciplinary and multiprofesssional guideline on DMARDs is timely for two major reasons: first, it was necessary to update the guideline produced by the British Society for Rheumatology (BSR) 5 yrs ago; and second,
|
Guideline eligibility and exclusion criteria |
|---|
|
Monitoring of treatment |
|---|
|
Audit proformas |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Lindsay, A. Gough, A. Layton, and S. Fraser Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long term, high cumulative dose methotrexate therapy: reply Rheumatology, November 1, 2009; 48(11): 1465 - 1465. [Full Text] [PDF]
|
|
|
|
|
|
B. Chikura, S. Lane, and J. K. Dawson Clinical expression of leflunomide-induced pneumonitis Rheumatology, September 1, 2009; 48(9): 1065 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. McLean-Tooke, C. Aldridge, S. Waugh, G. P. Spickett, and L. Kay Methotrexate, rheumatoid arthritis and infection risk--what is the evidence? Rheumatology, August 1, 2009; 48(8): 867 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Bhalla and M. Samaranayaka Comment on: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists Rheumatology, October 1, 2008; 47(10): 1591 - 1591. [Full Text] [PDF]
|
|
|
|
|
|
K. Chakravarty Comment on: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists: reply Rheumatology, October 1, 2008; 47(10): 1591 - 1591. [Full Text] [PDF]
|
|
|
|
|
|
P. Jobanputra BSR DMARD monitoring guidelines: sulfasalazine Rheumatology, October 1, 2008; 47(10): 1587 - 1588. [Full Text] [PDF]
|
|